Power Medical aims for $100m in public offering
This article was originally published in Clinica
Langhorne, Pennsylvania-based Power Medical Interventions (PMI), a developer of reusable computerized devices for delivering staples during surgery, is expecting to raise up to $100m in an initial public offering of its common stock. PMI aims to channel the proceeds toward the expansion of sales and marketing organisations, continuation of research efforts, and the possible acquisition of complementary businesses. Underwriters have been granted a 30-day option to purchase an additional undisclosed amount of shares. The company is looking to be listed under the symbol "PMII".
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.